Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07846683 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Name: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — clinical trial record (NCT07846683)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: AMETRINE-SC

StatusNot Yet Recruiting

PhasePhase 3

SponsorHoffmann-La Roche

Started2026-11-15

View on ClinicalTrials.gov ↗

Roche/Genentech

364 trials monitored

See 34 trials at risk

Ulcerative Colitis

582 trials monitored

See 29 trials at risk

The purpose of this study is to assess the efficacy and safety of subcutaneous induction with afimkibart in participants with moderately to severely active ulcerative colitis (UC).

Trial Details

NCT Number	NCT07846683
Lead Sponsor	Hoffmann-La Roche Collaborators: Chugai Pharmaceutical, Pfizer
Conditions	Moderately to Severely Active Ulcerative Colitis
Enrollment	350 participants
Start Date	2026-11-15
Primary Completion	2028-05-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-29